Go Deep
Anthem Biosciences Limited
Anthem Biosciences Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 18,137 | 84.0 | 15.71 | 0.02 | 851.10 |
| Sep 2026 | 18,137 | 84.0 | 15.71 | 0.02 | 851.10 |
| Sep 2026 | 18,135 | 86.2 | 15.71 | 0.02 | 851.10 |
| Oct 2026 | 17,308 | 84.7 | 15.80 | 0.02 | 855.75 |
| Oct 2026 | 16,375 | 85.0 | 15.92 | 0.02 | 862.30 |
Anthem Biosciences Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 4,182,180,000.0 | 6,109,430,000.0 | 4,231,530,000.0 | 5,500,270,000.0 |
| Net Profit | 1,199,410,000.0 | 1,897,580,000.0 | 928,170,000.0 | 1,734,280,000.0 |
| EPS | 2.1 | 3.4 | 1.6 | 3.1 |
Anthem Biosciences Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 21,243,330,000.0 | 18,445,530,000.0 | 14,193,700,000.0 | 10,569,240,000.0 | — |
| Net Profit | 5,917,920,000.0 | 4,512,600,000.0 | 3,673,100,000.0 | 3,851,850,000.0 | — |
| EPS | 10.6 | 8.0 | 6.5 | 6.9 | — |
Anthem Biosciences Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 34,292,900,000.0 | 28,075,830,000.0 | 23,981,140,000.0 | 20,144,580,000.0 | — |
| Total Liabilities | 3,867,740,000.0 | 3,977,190,000.0 | 4,734,590,000.0 | 2,737,900,000.0 | — |
| Total Equity | 30,425,160,000.0 | 24,098,640,000.0 | 19,246,550,000.0 | 17,406,680,000.0 | — |
Owes vs Owns
Anthem Biosciences Limited owed ₹0.11 for every ₹1 it owned in Mar 2026, down from ₹0.14 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.11× | 0.14× | 0.20× | 0.14× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Anthem Biosciences Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 27.4%Receivables 17.2%Inventory 3.6%Fixed assets (tangible) 31.1%Long-term investments 14.6%Other assets 6.1%
How it's funded — Mar 2026
Short-term debt 0.7%Long-term debt 0.8%Payables 2.3%Other liabilities 7.5%Shareholders' equity 88.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 938.5 | 483.7 | 642.9 | 835.1 |
| Receivables | 590.6 | 450.4 | 490.4 | 274.1 |
| Inventory | 124.5 | 340.4 | 211.3 | 129.4 |
| Fixed assets (tangible) | 1,066.5 | 1,007.4 | 837.7 | 634.3 |
| Intangible assets | 0.4 | 3.9 | 6.2 | 9.1 |
| Long-term investments | 500.3 | 265.5 | 12.6 | 6.2 |
| Other assets | 208.5 | 256.2 | 196.9 | 126.3 |
| Liabilities & equity | ||||
| Short-term debt | 23.3 | 61.9 | 120.9 | 28.9 |
| Long-term debt | 27.7 | 47.0 | 111.7 | 96.2 |
| Payables | 79.2 | 115.9 | 106.7 | 76.4 |
| Other liabilities | 256.5 | 172.8 | 134.3 | 72.3 |
| Shareholders' equity | 3,042.5 | 2,409.9 | 1,924.7 | 1,740.7 |
| Net tangible assets | 3,042.1 | 2,406.0 | 1,918.4 | 1,731.6 |
Anthem Biosciences Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 8,444,850,000.0 | 2,705,510,000.0 | 1,401,510,000.0 | 3,059,850,000.0 | — |
| Investing Activities | -7,016,210,000.0 | -1,465,650,000.0 | -2,214,590,000.0 | -3,760,160,000.0 | — |
| Financing Activities | -399,980,000.0 | -1,356,480,000.0 | -771,810,000.0 | 639,740,000.0 | — |